Risk stratification and secondary prevention post-myocardial infarction: insights from the EYESHOT Post-MI study

J Cardiovasc Med (Hagerstown). 2021 Jun 1;22(6):478-485. doi: 10.2459/JCM.0000000000001132.

Abstract

Aims: Clinical management of patients more than 1 year after acute myocardial infarction (MI) is challenging. Patient risk stratification may help to establish therapeutic priorities. We aimed to describe the comprehensive risk profile and management of patients with prior MI.

Methods: We analyzed data from the EYESHOT Post-MI study, which evaluated the management of patients 1-3 years after MI. The risk profile of participants was defined according to the qualifying high-risk features of the PEGASUS-TIMI 54 trial (history of diabetes, history of recurrent MI, angiographic evidence of multivessel coronary disease, chronic kidney disease with estimated glomerular filtration rate <60 ml/min, age ≥65 years). Patients were classified into five subgroups according to the presence of zero, one, two, three, or more than three features.

Results: Of the 1633 patients in the EYESHOT Post-MI study, 1008 could be stratified according to PEGASUS-TIMI 54 high-risk features. About 22% of patients had no high-risk features, whereas 25% showed at least three features. The prevalence of patients with specific clinical severity indicators was progressively higher with the increasing number of high-risk features. Dual antiplatelet therapy and oral anticoagulation were more frequently used in patients with an increasing number of high-risk features (P for trend <0.0001). Lipid-lowering therapies were less frequently prescribed in patients with a higher number of features (P for trend 0.006 for statins; P for trend 0.007 for ezetimibe).

Conclusion: Higher-risk post-MI patients, identified by PEGASUS-TIMI 54 high-risk features, showed an increased prevalence of major clinical severity indicators. Secondary prevention therapies were not adequately implemented in higher-risk patients.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Aftercare / methods
  • Aged
  • Comorbidity
  • Coronary Artery Disease* / diagnosis
  • Coronary Artery Disease* / drug therapy
  • Coronary Artery Disease* / epidemiology
  • Female
  • Health Services Needs and Demand
  • Heart Disease Risk Factors
  • Humans
  • Italy / epidemiology
  • Male
  • Myocardial Infarction* / complications
  • Myocardial Infarction* / epidemiology
  • Myocardial Infarction* / therapy
  • Platelet Aggregation Inhibitors / administration & dosage
  • Risk Adjustment* / methods
  • Risk Adjustment* / organization & administration
  • Risk Assessment / methods*
  • Secondary Prevention* / methods
  • Secondary Prevention* / standards
  • Severity of Illness Index

Substances

  • Platelet Aggregation Inhibitors